A new twist in neuroendocrine tumor research: Pacak-Zhuang syndrome, HIF-2α as the major player in its pathogenesis and future therapeutic options
Language English Country Czech Republic Media print-electronic
Document type Journal Article, Review
PubMed
24781045
DOI
10.5507/bp.2014.021
Knihovny.cz E-resources
- MeSH
- Carcinogenesis genetics MeSH
- Humans MeSH
- Mutation MeSH
- Paraganglioma drug therapy genetics MeSH
- Polycythemia congenital drug therapy genetics MeSH
- Somatostatinoma drug therapy genetics MeSH
- Syndrome MeSH
- Basic Helix-Loop-Helix Transcription Factors genetics MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- endothelial PAS domain-containing protein 1 MeSH Browser
- Basic Helix-Loop-Helix Transcription Factors MeSH
UNLABELLED: Backround. There is increasing evidence of the role of hypoxia or pseudohypoxia in tumorigenesis, including pheochromocytoma (PHEO) and paraganglioma (PGL). (Pseudo)hypoxia leads to activation of hypoxia-inducible transcription factors (HIFs) and thus, promotes the transcription of hypoxia-responsive genes which are involved in tumorigenesis. Recently identified is a new syndrome consisting of multiple and recurrent PGLs or PHEOs, somatostatinoma, and congenital polycythemia, due to somatic hypoxia-inducible factor 2α gene (HIF2A) mutations. METHODS AND RESULTS: PubMed and Web of Science online databases were used to search reviews and original articles on the HIF, PHEO/PGL, and Pacak-Zhuang syndrome. CONCLUSIONS: The novel somatic and germline gain-of-function HIF2A mutations described latterly emphasize the role of the HIF-2α in the PHEO/PGL development and these findings designate HIF, especially HIF-2α, as a promising treatment target.
References provided by Crossref.org